Biology Reference
In-Depth Information
Homma S, Sakamoto T, Hegab AE, Saitoh W, Nomura A, Ishii Y, Morishima Y, Iizuka T,
Kiwamoto T, Matsuno Y, Massoud HH, Massoud HM, Hassanein KM, Sekizawa K (2006)
Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary
disease: relationship to interleukin 13 gene polymorphism. Int J Mol Med 18:933-939
Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP
breakdown. Trends Biochem Sci 35:91-100
Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic
target. Drug Discov Today 10:1503-1519
Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in
the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP
signaling. Circ Res 100:950-966
Huston E, Lynch MJ, Mohamed A, Collins DM, Hill EV, MacLeod R, Krause E, Baillie GS,
Houslay MD (2008) EPAC and PKA allow cAMP dual control over DNA-PK nuclear
translocation. Proc Natl Acad Sci USA 105:12791-12796
Ichikawa H, Okamoto S, Kamada N, Nagamoto H, Kitazume MT, Kobayashi T, Chinen H,
Hisamatsu T, Hibi T (2008) Tetomilast suppressed production of proinflammatory cytokines
from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. Inflamm
Bowel Dis 14:1483-1490
Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential
for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99:7628-7633
Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M (1999) Impaired growth and fertility of
cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 96:
11998-12003
Jones NA, Boswell-Smith V, Lever R, Page CP (2005) The effect of selective phosphodiesterase
isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18:93-101
Jones NA, Leport M, Holand T, Vos T, Morgan M, Fink M, Pruniaux MP, Berthelier C, O'Connor
BJ, Bertrand C, Page CP (2007) Phosphodiesterase (PDE) 7 in inflammatory cells from patients
with asthma and COPD. Pulm Pharmacol Ther 20:60-68
Kanehiro A, Ikemura T, Makela MJ, Lahn M, Joetham A, Dakhama A, Gelfand EW (2001)
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflam-
mation in a model of secondary allergen challenge. Am J Respir Crit Care Med 163:173-184
Keshavarzian A, Mutlu E, Guzman JP, Forsyth C, Banan A (2007) Phosphodiesterase 4 inhibitors
and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert
Opin Investig Drugs 16:1489-1506
Kobayashi K, Suda T, Manabe H, Miki I (2007) Administration of PDE4 inhibitors suppressed the
pannus-like inflammation by inhibition of cytokine production by macrophages and synovial
fibroblast proliferation. Mediat Inflamm 2007:58901
Kohyama T, Liu X, Zhu YK, Wen FQ, Wang HJ, Fang Q, Kobayashi T, Rennard SI (2002)
Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation
induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol
27:487-494
Kranz M, Wall M, Evans B, Miah A, Ballantine S, Delves C, Dombroski B, Gross J, Schneck J,
Villa JP, Neu M, Somers DO (2009) Identification of PDE4B Over 4D subtype-selective
inhibitors revealing an unprecedented binding mode. Bioorg Med Chem 17:5336-5341
Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M, Webb DC, Foster PS (2003)
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine
chronic asthma. J Pharmacol Exp Ther 307:349-355
Kung TT, Crawley Y, Luo B, Young S, Kreutner W, Chapman RW (2000) Inhibition of
pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram:
involvement of endogenously released corticosterone and catecholamines. Br J Pharmacol
130:457-463
Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C (2003) In vivo efficacy in airway
disease models of N-(3, 5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyo
Search WWH ::




Custom Search